250 related articles for article (PubMed ID: 16877732)
1. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.
Mamelak AN; Rosenfeld S; Bucholz R; Raubitschek A; Nabors LB; Fiveash JB; Shen S; Khazaeli MB; Colcher D; Liu A; Osman M; Guthrie B; Schade-Bijur S; Hablitz DM; Alvarez VL; Gonda MA
J Clin Oncol; 2006 Aug; 24(22):3644-50. PubMed ID: 16877732
[TBL] [Abstract][Full Text] [Related]
2. Imaging glioma extent with 131I-TM-601.
Hockaday DC; Shen S; Fiveash J; Raubitschek A; Colcher D; Liu A; Alvarez V; Mamelak AN
J Nucl Med; 2005 Apr; 46(4):580-6. PubMed ID: 15809479
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601).
Mamelak AN; Jacoby DB
Expert Opin Drug Deliv; 2007 Mar; 4(2):175-86. PubMed ID: 17335414
[TBL] [Abstract][Full Text] [Related]
4. An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial.
Tatter SB; Shaw EG; Rosenblum ML; Karvelis KC; Kleinberg L; Weingart J; Olson JJ; Crocker IR; Brem S; Pearlman JL; Fisher JD; Carson K; Grossman SA;
J Neurosurg; 2003 Aug; 99(2):297-303. PubMed ID: 12924704
[TBL] [Abstract][Full Text] [Related]
5. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Reardon DA; Quinn JA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Dowell JM; Rich JN; Vredenburgh JJ; Desjardins A; Sampson JH; Gururangan S; Wong TZ; Badruddoja MA; Zhao XG; Bigner DD; Zalutsky MR
J Nucl Med; 2006 Jun; 47(6):912-8. PubMed ID: 16741299
[TBL] [Abstract][Full Text] [Related]
6. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Bigner DD; Brown MT; Friedman AH; Coleman RE; Akabani G; Friedman HS; Thorstad WL; McLendon RE; Bigner SH; Zhao XG; Pegram CN; Wikstrand CJ; Herndon JE; Vick NA; Paleologos N; Cokgor I; Provenzale JM; Zalutsky MR
J Clin Oncol; 1998 Jun; 16(6):2202-12. PubMed ID: 9626222
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
Akabani G; Reardon DA; Coleman RE; Wong TZ; Metzler SD; Bowsher JE; Barboriak DP; Provenzale JM; Greer KL; DeLong D; Friedman HS; Friedman AH; Zhao XG; Pegram CN; McLendon RE; Bigner DD; Zalutsky MR
J Nucl Med; 2005 Jun; 46(6):1042-51. PubMed ID: 15937318
[TBL] [Abstract][Full Text] [Related]
8. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
[TBL] [Abstract][Full Text] [Related]
9. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors.
Riva P; Arista A; Franceschi G; Frattarelli M; Sturiale C; Riva N; Casi M; Rossitti R
Cancer Res; 1995 Dec; 55(23 Suppl):5952s-5956s. PubMed ID: 7493376
[TBL] [Abstract][Full Text] [Related]
10. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects.
McLendon RE; Akabani G; Friedman HS; Reardon DA; Cleveland L; Cokgor I; Herndon JE; Wikstrand C; Boulton ST; Friedman AH; Bigner DD; Zalutsky MR
Nucl Med Biol; 2007 May; 34(4):405-13. PubMed ID: 17499730
[TBL] [Abstract][Full Text] [Related]
11. Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources.
Gutin PH; Phillips TL; Wara WM; Leibel SA; Hosobuchi Y; Levin VA; Weaver KA; Lamb S
J Neurosurg; 1984 Jan; 60(1):61-8. PubMed ID: 6358430
[TBL] [Abstract][Full Text] [Related]
12. Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice.
Shen S; Khazaeli MB; Gillespie GY; Alvarez VL
J Neurooncol; 2005 Jan; 71(2):113-9. PubMed ID: 15690125
[TBL] [Abstract][Full Text] [Related]
13. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
[TBL] [Abstract][Full Text] [Related]
14. [Iridium 192 brachytherapy of supra-tentorial high grade glioma recurring in irradiated areas: technique and preliminary results of the Pitié-Salpêtrière hospital group].
Boisserie G; Cornu P; Dormont D; Sahel M; Hardiman C; Tep B; Mandin AM; Barret C; Faillot T; Delattre JY; Monjour A; Poisson M; Marsault C; Philippon J; Simon JM; Baillet F; Mazeron JJ
Bull Cancer Radiother; 1996; 83(3):144-52. PubMed ID: 8977564
[TBL] [Abstract][Full Text] [Related]
15. [Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV)].
Pöpperl G; Götz C; Gildehaus FJ; Yousry TA; Reulen HJ; Hahn K; Tatsch K
Nuklearmedizin; 2002 Jun; 41(3):120-8. PubMed ID: 12109031
[TBL] [Abstract][Full Text] [Related]
16. Safety and feasibility of convection-enhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients.
Patel SJ; Shapiro WR; Laske DW; Jensen RL; Asher AL; Wessels BW; Carpenter SP; Shan JS
Neurosurgery; 2005 Jun; 56(6):1243-52; discussion 1252-3. PubMed ID: 15918940
[TBL] [Abstract][Full Text] [Related]
17. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
18. Survival following interstitial brachytherapy for recurrent malignant glioma.
Kitchen ND; Hughes SW; Taub NA; Sofat A; Beaney RP; Thomas DG
J Neurooncol; 1994; 18(1):33-9. PubMed ID: 8057132
[TBL] [Abstract][Full Text] [Related]
19. Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors.
Riva P; Arista A; Tison V; Sturiale C; Franceschi G; Spinelli A; Riva N; Casi M; Moscatelli G; Frattarelli M
Cancer; 1994 Feb; 73(3 Suppl):1076-82. PubMed ID: 8306250
[TBL] [Abstract][Full Text] [Related]
20. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results.
Paganelli G; Bartolomei M; Ferrari M; Cremonesi M; Broggi G; Maira G; Sturiale C; Grana C; Prisco G; Gatti M; Caliceti P; Chinol M
Cancer Biother Radiopharm; 2001 Jun; 16(3):227-35. PubMed ID: 11471487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
